Sativex regulatory update

The German Institute for Quality and Efficiency in Health Care (IQWiG) issued a preliminary benefit assessment that assigned Sativex from GW Pharmaceuticals a rating of "no additional benefit" for the indication of treating spasticity in multiple sclerosis (MS) patients. The agency said the data provided by GW were not suited for comparison with IQWiG's comparator of "optimized standard therapy" - baclofen, tizanidin or other anti-spasticity drugs. ...